* Safety review committee approves continued evaluation of 20 mbq/kg

* the Safety Review Committee (SRC) for the ongoing LYMRIT 37-01 clinical trial of Betalutin in non-Hodgkin's Lymphoma (NHL) has reviewed safety data from the study and approved continued clinical evaluation of 20 MBq/kg Betalutin administered after pre-dosing with 100 mg/m2 lilotomab

* "Recommendation from the SRC represents another important milestone for the development of Betalutin, in line with our strategy and established timelines" Source text for Eikon: Further company coverage: